Mexico Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By State - Forecasts From 2025 To 2030

Mexico Pain Management Drugs Market Size:

The Mexican pain management drugs market is expected to grow at a CAGR of 2.45% from 2025 to 2030.

The growing middle-class population is correspondingly leading to a rise in the prevalence of lifestyle-related chronic diseases in the country. According to the Oncology Department of Mexico’s National Institute of Cancer (INCAN), 7 out of 10 adults are overweight, one of the leading risk factors for most types of cancer, including breast cancer, prostate cancer, and colon cancer.

Moreover, the rising prevalence of type 2 diabetes is further expanding the population base suffering from joint pain and back pain. According to the World Health Organization (WHO), the country accounts for the most hospitalizations related to diabetes among the Organization for Economic Co-operation and Development’s (OECD) 35 countries. The above factors are bolstering the demand for various pain management drugs to treat different causes of pain. Additionally, the escalating number of surgical procedures performed in Mexican hospitals is also driving the growth of pain management drugs in the country.

Another major driver of the Mexican pain management drugs market is the growing medical tourism industry in the country, supported by the OTC (over-the-counter) availability of cheaper prescription drugs. Rising healthcare costs and wait times in the U.S. and Canada are encouraging people to turn to Mexico to purchase cheaper drugs and medicines.

According to the U.S. government estimates, nearly 1 million people in California alone visit Mexico annually for health care services, including to buy prescription drugs. The presence of larger independent pharmacy chains and discount drug stores in Mexico, as well as rising sales of OTC drugs through the non-pharmacy sector, is attracting several U.S. companies to set up joint development deals with Mexican retailers to boost the sales of OTC drugs, thus positively impacting the pain management drugs market growth. This includes the venture between K-Mart and the Mexican retailer and departmental store company, El Puerto de Liverpool, Price Co’s discount warehouse agreement with Comercial Mexicana, and Wal-Mart’s price-club developments with Mexico’s largest retailer, Cifra.

Mexico Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By State
  • Mexico City
  • Jalisco
  • Nuevo Leon
  • Baja California
  • Guerrero

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. MEXICO PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. MEXICO PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. MEXICO PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. MEXICO PAIN MANAGEMENT DRUGS MARKET BY STATE

8.1. Introduction

8.2. Mexico City

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Jalisco

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Nuevo Leon

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Baja California

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Guerrero

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Bayer Mexico

10.2. Boehringer Ingelheim Mexico

10.3. Novartis Pharmaceuticals Corporation (Novartis AG)

10.4. Eli Lilly and Company

10.5. Pfizer Inc.

10.6. Abbott Laboratories

10.7. Johnson & Johnson

10.8. Sanofi Mexico

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Bayer Mexico

Boehringer Ingelheim Mexico

Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

Abbott Laboratories

Johnson & Johnson

Sanofi Mexico